Globe Newswire (Mon, 30-Mar 4:30 PM ET)
Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference
Globe Newswire (Tue, 24-Feb 4:30 PM ET)
Globe Newswire (Thu, 5-Feb 10:45 AM ET)
Market Chameleon (Tue, 2-Dec 4:54 AM ET)
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
Jasper Therapeutics - Class A trades on the NASDAQ stock market under the symbol JSPR.
As of April 10, 2026, JSPR stock price declined to $0.80 with 776,771 million shares trading.
JSPR has a beta of 1.85, meaning it tends to be more sensitive to market movements. JSPR has a correlation of 0.06 to the broad based SPY ETF.
JSPR has a market cap of $22.45 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, JSPR traded as high as $31.01 and as low as $.62.
The top ETF exchange traded funds that JSPR belongs to (by Net Assets): VTI, VXF, IWC.
JSPR has underperformed the market in the last year with a price return of -77.8% while the SPY ETF gained +25.2%. JSPR has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -46.9% and -27.7%, respectively, while the SPY returned -1.8% and +5.3%, respectively.
JSPR support price is $.77 and resistance is $.88 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that JSPR shares will trade within this expected range on the day.
